MIRA INFORM REPORT
|
Report No. : |
329336 |
|
Report Date : |
29.06.2015 |
IDENTIFICATION DETAILS
|
Name : |
LEK D.D. |
|
|
|
|
Registered Office : |
Verovˇskova ulica 57 1000 Ljubljana |
|
|
|
|
Country : |
Slovenia |
|
|
|
|
Financials (as on) : |
31.12.2014 |
|
|
|
|
Date of Incorporation : |
14.08.2002 |
|
|
|
|
Legal Form : |
Joined stocked Company |
|
|
|
|
Line of Business : |
Manufacture of pharmaceutical preparations. |
|
|
|
|
No. of Employee : |
2978 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No complaints |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31, 2015
|
Country Name |
Previous Rating (31.12.2014) |
Current Rating (31.03.2015) |
|
Slovenia |
B1 |
B1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
SLOVENIA ECONOMIC OVERVIEW
With excellent infrastructure, a well-educated work force, and a strategic location between the Balkans and Western Europe, Slovenia has one of the highest per capita GDPs in Central Europe, despite having suffered a protracted recession in 2008-2009 in the wake of the global financial crisis. Slovenia became the first 2004 European Union entrant to adopt the euro (on 1 January 2007) and has experienced one of the most stable political transitions in Central and Southeastern Europe. In March 2004, Slovenia became the first transition country to graduate from borrower status to donor partner at the World Bank. In 2007, Slovenia was invited to begin the process for joining the OECD; it became a member in 2012. However, long-delayed privatizations, particularly within Slovenia’s largely state-owned and increasingly indebted banking sector, have fueled investor concerns since 2012 that the country would need EU-IMF financial assistance. In 2013, the European Commission granted Slovenia permission to begin recapitalizing ailing lenders and transferring their nonperforming assets into a “bad bank” established to restore bank balance sheets. Export-led growth fueled by demand in larger European markets pushed GDP growth to 2.6% in 2014, while stubbornly-high unemployment fell slightly to 13%. PM CERAR’s government took office in September 2014, pledging to press ahead with commitments to privatize a select group of state-run companies, rationalize public spending, and further stabilize the banking sector.
|
Source
: CIA |
Company
identification
Lek
d.d. Phone 01
580 21 11
Verovˇskova
ulica 57 Telefax
01 568 35 17
1000
Ljubljana E-Mail info@lek.si
Slovenia
Web
www.lek.si
Crefo
Nr. 9270022631 Registration: Ljubljana
Statistical
Nr. 1732811 Registration Nr. 13654200
Tax Nr. SI87916452 Status Active
Economic
situation
Business
connection Business connection are
premissible
Terms
of payment Within agreed terms
Basic
information
Legal
form
Joined
stocked Company
Founded
14/08/2002
as d.o.o. - Limited liability company (Ltd.)
21/07/2004
as Joined stocked Company
last
entry on 04.06.2015
original
with the company name Novartis Pharma d.o.o.
since
10.07.2003 with the company name Novartis Pharma Storitve d.d., \
since
30.9.2004 with the company name Lek d.d.
on
30.9.2004 incorporation of the daughter company LEK d.d. (company \
nu.
5043425,
established
already in 1946) into parent company Novartis Pharma \
Storitve
d.d. and
at
the same time change of the company name from Novartis Pharma \
Storitve
d.d. into Lek d.d.
the
company LEK d.d. (company nu. 5043425) was on 7.12.2004 from the \
register
erased
Registration
21/07/2004,
Ljubljana, 13654200
Statistical
Nr.: 1732811
Tax
Nr.: SI87916452
Owners and Capital
|
Crefo Nr. |
|
Name /
Address / Status |
From |
Share |
|
Head
shareholders |
|
|
||
|
9270022638 |
|
NOVARTIS
PHARMA AG |
|
100 % |
|
|
|
Lichtstr. 35, Basel Switzerland |
|
|
Registered capital
|
Date |
|
Currency |
Value |
|
|
|
EUR |
48.402.003 |
Management
|
Crefo Nr. |
|
Name / Address / Status |
Since |
Power of attorney |
||
|
Board of Directors |
|
|
||||
|
9270150860 |
|
Board member |
|
|
||
|
|
|
Alesˇ Rokavec |
|
|
||
|
|
|
Bratovsevaˇ plosˇcadˇ 33, 1000 Ljubljana Slovenia |
|
|
||
|
|
|
|
|
|
||
|
9270162012 |
|
Member of the board of directors Daniel Michalek Katrezˇeva pot 24, 1231 Ljubljana - Cˇ rnucˇe Slovenia |
|
|
||
|
|
|
|
|
|
||
|
9270038404 |
|
Board member |
|
|
||
|
|
|
ˇ |
|
|
||
|
|
|
Ksenija Butenko Cerne |
|
|
||
|
|
|
Moskriˇcevaˇ ulica 2a, 1000 Ljubljana Slovenia |
|
|
||
|
|
|
|
|
|
||
|
9270159853 |
|
Board member |
|
|
||
|
|
|
Marjan Novak |
|
|
||
|
|
|
Dobrunjska cesta 6A, 1261 Ljubljana-Dobrunje |
|
|
||
|
|
|
Slovenia |
|
|
||
|
|
|
|
|
|
||
|
|
|
Board member |
|
|
||
|
|
|
Samo Rosˇ |
|
|
||
|
|
|
Mladinska ulica 15, 1000 Ljubljana Slovenia |
|
|
||
|
|
|
|
|
|
||
|
9270030855 |
|
Chairman of the board |
|
|
||
|
|
|
Vojmir Urlep |
|
|
||
|
|
|
Roznaˇ ulica 13, 1370 Logatec Slovenia |
|
|
||
|
9270038397 |
|
Board member |
|
|
||
|
|
|
Zvonko Bogdanovski Roˇzna dolina, Cesta VI 1a, 1000 Ljubljana
Slovenia |
|
|
||
Supervisory Board
|
9270157751 |
chairman
of the supervisory board Francesco
Balestrieri Herterichstrasse
31, 81479 M¨unchen Germany |
|
|
|
|
|
|
|
|
9270157628 |
member
of the supervisory board Jeffrey
Martin Rope Eggstrasse
25, 6315 Ober¨ageri Switzerland |
|
|
|
|
|
|
|
|
9270151539 |
member
of the supervisory board Peter
Svete Laze
pri Borovnici 10A, 1353 Borovnica Slovenia |
|
|
|
|
|
|
|
|
9270160291 |
member
of the supervisory board Richard
David Francis INDUSTRIESTRASSE
25, 83607 HOLZKIRCHEN Germany |
|
|
|
|
|
|
|
|
9270156094 |
member
of the supervisory board Ulrich
Mager Knut Elsternweg
8, 4104 Bottmingen Switzerland |
|
|
|
|
|
|
|
|
9270158918 |
member
of the supervisory board Vesna
Premovi´c Celovˇska
cesta 263, 1000 Ljubljana Slovenia |
|
|
Company addresses
|
Valid from |
Residence
address |
Valid until |
|
|
Verovˇskova ulica 57, 1000 Ljubljana, Slovenia Phone: 01 580 21 11 Telefax: 01 568 35 17 E-Mail: info@lek.si Web: www.lek.si |
|
Subsidiaries
|
Crefo Nr. |
|
Name / Address / Status |
Valid from |
Share |
|
|
|
|
|
|
|
Owner |
|
|
|
|
|
9270074063 |
|
NOVARTIS VETERINA d.o.o. |
|
2.086.463 EUR |
|
|
|
Statistical Nr.: 2036568 |
|
|
|
|
|
Verovskovaˇ ulica 57, 1000 Ljubljana Slovenia |
|
|
|
|
|
|
|
|
|
9270038426 |
|
Hotel Lek d.o.o. Slovenia |
|
100 % |
|
|
|
|
|
|
|
9270038428 |
|
Novartis Veterina d.o.o. Slovenia |
|
100 % |
|
|
|
|
|
|
|
9270038430 |
|
Lek Zagreb d.o.o. Croatia |
|
100 % |
|
|
|
|
|
|
|
9270038431 |
|
Lek Skopje d.o.o. Macedonia |
|
100 % |
|
|
|
|
|
|
|
9270038432 |
|
Lek Ljubljana Holding GmbH Austria |
|
100 % |
|
|
|
|
|
|
|
9270038433 |
|
ˇ |
|
74 % |
|
|
Cistilna naprava Lendava d.o.o. Slovenia |
|
||
|
|
|
|
|
|
|
9270038434 |
|
Lek Pharmaceuticals Inc. USA |
|
100 % |
|
|
|
|
|
|
|
9270071628 |
|
IEDC d.o.o. |
|
158.571 EUR |
|
|
|
Statistical Nr.: 1197843 |
|
|
|
|
|
Presernovaˇ cesta 33, 4260 Bled Slovenia |
|
|
|
|
|
|
|
|
|
9270071640 |
|
ˇ |
|
10.606,59 EUR |
|
|
TEHNOLOSKI PARK LJUBLJANA d.o.o. |
|
||
|
|
|
Statistical Nr.: 5911508 |
|
|
|
|
|
Tehnoloskiˇ park 19, 1000 Ljubljana Slovenia |
|
|
|
Head shareholders |
|
|
||
|
9270038429 |
|
Sandoz d.d. |
|
100 % |
|
|
|
Statistical Nr.: 2159287 |
|
|
|
|
|
Verovskovaˇ ulica 57, 1000 Ljubljana Slovenia |
|
|
Business activities
|
Main activity |
Nace |
|
Manufacture of pharmaceutical preparations |
21.20 |
|
|
|
|
Additional activities |
Nace |
Company activity
manufacture
of pharmaceutical preparations,
chemicals,
cosmetics, dental products,
research
and development, quality control,
advisory
engineering, tourism, export-import
representation
and mediation
(all
this activities are within the company since
september
2004 after the incorporation
of
the company Lek d.d., before the activity
was
only managing of the companies)
headquarters
and the part of the manufacture premises
are
located on the address above
branc
offices are located:
in
Menge_s, Kolodvorska cesta 27 (manufacture of
raw
materials for the company use and for
further
sale), - in Lendava, Trimlini 2D,
(manufacture
of cosmetics, manufacture of
pharmaceutical
raw materials) - in Lipovci, Lipovci 251D, Beltinci
(veterinary
programme) - in Prevalje, Perzonali 47
(dental
programme) - Ljubljana, Celov_ska cesta 135
(research
and development)
the
company has wide sales net and a great deal of
licence
partners who transfered their sales rights for
their
products on the company, for example:
Meck
and Co. (USA), Farmitalia (Italy), E.Merck (Germany),
Ivoclar/Vivadent
(Lichtenstein), Revlon (USA) etc.
selling
structure: 77\% Central-and Easteurope, 10\% Asia and
Latin
Amerika,
9\% Slovenia, 2\% Africa,Australia, 2\% Westeuropa, USA, Canada
Economic
data
|
Date |
Turnover |
Employees |
|
2008 |
729.193.527 EUR |
2500 |
|
2009 |
581.597.375 EUR |
2435 |
|
2010 |
575.865.113 EUR |
2472 |
|
2011 |
645.328.141 EUR |
2500 |
|
2012 |
697.910.862 EUR |
2616 |
|
2013 |
776.424.714 EUR |
2819 |
|
2014 |
784.842.241 EUR |
2978 |
Group Lek
Annual
turnover 2013 EUR 963.371.060,--
Profit
2013 EUR 88.114.060,--
Annual
turnover 2012 EUR 820.312.152,--
Profit
2012 EUR 73.099.020,--
Annual
turnover 2011 EUR 773.551.330,--
Profit
2011 EUR 79.654.660,--
Annual turnover 2010 EUR 734.517.330,--
Profit
2010 EUR 67.003.820,--
Annual
turnover 2009 EUR 731.591.573,--
Profit
2009 EUR 48.747.940,--
Annual
turnover 2008 EUR 831.502.677,--
Profit
2008 EUR 97.989.770,--
Annual
turnover 2007 EUR 973.760.702,--
Profit 2007 EUR 81.200.979,--
Import /
Export
|
|
Import |
Export |
|
Percentage |
Unknown |
Unknown |
|
|
|
|
|
Countries |
India, Germany, Spain, Japan, USA, China, Italy, Switzerland, Austria |
Unknown |
Properties
|
Name |
Detail |
Currency |
Value |
|
Land and buildings |
Company’s property |
EUR |
122.586.552 |
|
|
per 31.12.2014 |
|
|
Supplementary data
Remarks
company
name:
LEK
farmacevtska druˇzba d.d.
firma
v angleˇskem jeziku: Lek Pharmaceuticals d.d.
firma
v franc.j:Societe Pharmaceutique Lek d.d.
participation
in capital:
Hotel
Lek d.o.o. Kranjska Gora(100% share)
Sandoz
d.d.Ljubljana(100% share)
Cˇ
N Lendava d.o.o. (74,5% share)
Novartis
Veterina d.o.o. Ljubljana (100% share)
Lek
Ljubljana Holding GmbH Austria(100% share)
(stand
per 31.12.2013)
Representations
are located in BiH, Georgien, Ukraine, Kasachstan,
Poland, Russia, Usbekistan, Belaruss
Banks
|
Code |
Bank name / Address |
Account Nr. |
|
124 |
RAIFFEISEN BANKA d.d. |
SI56 242039062678839 |
|
|
Slovenska ulica 17, 2000 Maribor , 2000, |
|
Main
indices
Payment experience and credit opinion
|
|
Terms
of payment |
Within
agreed terms |
|
|
|
Business
connection |
Business
connection are premissible |
|
|
Business development |
|
|
|
|
|
Company development |
Constant |
|
Events
No negative events registered.
Balances
sheet
Balance
31.12.2014
The enclosed balance
of 2014 is originated from official source, it is not authenticated by the
auditor.
31.12.2013
The enclosed balance of
2013 is originated from official source, it is not authenticated by the
auditor.
31.12.2012
The enclosed balance
of 2012 is originated from official source, it is not authenticated by the
auditor.
31.12.2011 The enclosed balance of 2011 is originated from
official source, it is authenticated by the auditor .
|
|
|
31/12/2014 |
31/12/2013 |
31/12/2012 |
31/12/2011 |
|
Name |
Ref. |
1 |
1 |
1 |
1 |
|
EUR |
EUR |
EUR |
EUR |
||
|
|
|
balance |
balance |
balance |
balance |
|
|
|
|
|
|
|
|
ASSETS (AKTIVA) |
|
903.742.699 |
852.331.589 |
869.539.500 |
873.377.827 |
|
LONG-TERM
ASSETS |
|
635.101.230 |
617.809.224 |
602.515.767 |
579.329.027 |
|
Intangible
assets and long-term deferred costs |
|
341.330.073 |
341.307.248 |
341.522.677 |
341.658.420 |
|
and
accrued revenues |
|
|
|
|
|
|
Intangible
assets |
|
341.308.823 |
341.255.159 |
341.494.941 |
341.685.420 |
|
Long-term
deferred costs and accrued revenues |
|
21.250 |
52.089 |
27.736 |
0 |
|
Tangible
fixed assets |
|
288.198.078 |
270.928.897 |
255.420.011 |
227.756.959 |
|
Long-term
financial investments and Real estate |
|
5.573.079 |
5.573.079 |
5.573.079 |
9.837.393 |
|
investments |
|
|
|
|
|
|
Investment
property |
|
0 |
0 |
0 |
0 |
|
Long-term
financial investments |
|
5.573.079 |
5.573.079 |
5.573.079 |
9.837.393 |
|
Long-term
operating receivables |
|
0 |
0 |
0 |
49.255 |
|
Deferred
receivables for taxes |
|
0 |
0 |
0 |
0 |
|
SHORT-TERM
ASSETS |
|
268.533.809 |
233.862.071 |
266.312.464 |
293.615.054 |
|
Assets (group
for estrange) for sell |
|
0 |
0 |
0 |
0 |
|
Inventories |
|
164.927.011 |
142.106.025 |
148.673.052 |
112.371.786 |
|
|
|
31/12/2014 |
31/12/2013 |
31/12/2012 |
31/12/2011 |
|
Name |
Ref. |
1 |
1 |
1 |
1 |
|
EUR |
EUR |
EUR |
EUR |
||
|
|
|
balance |
balance |
balance |
balance |
|
Short-term
financial investments |
|
1.561.857 |
82.675 |
2.372.852 |
60.610.715 |
|
Short-term
operating receivables |
|
101.828.454 |
91.608.842 |
115.155.461 |
117.730.840 |
|
Cash
assets |
|
216.487 |
64.529 |
111.099 |
2.901.713 |
|
Short-term
deferred costs and accrued revenues |
|
107.660 |
660.294 |
711.269 |
433.746 |
|
Off-balance
sheet items |
|
22.957.811 |
16.861.813 |
4.606.067 |
0 |
|
LIABILITIES |
|
903.742.699 |
852.331.589 |
869.539.500 |
873.377.827 |
|
CAPITAL |
|
500.361.526 |
524.286.847 |
505.451.020 |
499.520.850 |
|
Called-up
capital |
|
48.402.003 |
48.402.003 |
48.402.003 |
48.402.003 |
|
Basic
(subscribed) capital |
|
48.402.003 |
48.402.003 |
48.402.003 |
48.402.003 |
|
Non called-up
capital (deductive item) |
|
0 |
0 |
0 |
0 |
|
Capital
reserves |
|
375.595.036 |
375.595.036 |
375.595.036 |
375.595.036 |
|
Reserves
from profit |
|
0 |
0 |
0 |
0 |
|
Surplus
from revaluation |
|
-3.222.689 |
0 |
0 |
0 |
|
Retained
net |
|
10.289.808 |
11.453.981 |
5.523.811 |
1.663.619 |
|
Net
business result for the business year |
|
69.297.368 |
88.835.827 |
75.930.170 |
73.860.192 |
|
PROVISIONS AND
LONG-TERM ACCRUED |
|
24.904.747 |
18.998.986 |
35.674.035 |
31.103.312 |
|
COSTS AND
DEFERRED REVENUES |
|
|
|
|
|
|
FINANCIAL
AND BUSINESS LIABILITIES |
|
364.032.638 |
294.400.163 |
314.719.161 |
332.816.835 |
|
LONG-TERM
LIABILITIES |
|
5.564.134 |
5.721.406 |
5.721.406 |
7.258.460 |
|
Long-term
financial liabilities |
|
0 |
0 |
0 |
0 |
|
Long-term
operating liabilities |
|
0 |
0 |
0 |
0 |
|
Deferred
liabilities for taxes |
|
5.564.134 |
5.721.406 |
5.721.406 |
7.258.460 |
|
SHORT-TERM
LIABILITIES |
|
358.468.504 |
288.678.757 |
308.997.755 |
325.558.375 |
|
Liabilities,
included in groups for estrange |
|
0 |
0 |
0 |
0 |
|
Short-term
financial liabilities |
|
229.229.482 |
172.812.224 |
198.804.583 |
21.385.529 |
|
Short-term
operating liabilities |
|
129.239.022 |
115.866.533 |
110.193.172 |
304.172.846 |
|
SHORT-TERM ACCRUED COSTS AND DE- |
|
14.443.788 |
14.645.593 |
13.695.284 |
9.936.830 |
|
FERRED
REVENUES |
|
|
|
|
|
|
Off-balance
sheet items |
|
22.957.811 |
16.861.813 |
4.606.067 |
0 |
Profit and
loss accounts
31.12.2014
The enclosed profit and
loss account of 2014 is originated from official source, it is not
authenticated by the auditor.
31.12.2013
The enclosed profit
and loss account of 2013 is originated from official source, it is not
authenticated by the auditor.
31.12.2012
The enclosed profit
and loss account of 2012 is originated from official source, it is not
authenticated by the auditor.
31.12.2011 The enclosed profit and loss account of 2011
is originated from official source, it is authenticated by the auditor .
|
|
|
31/12/2014 |
31/12/2013 |
31/12/2012 |
31/12/2011 |
|
|
|
1 |
1 |
1 |
1 |
|
Name |
Ref. |
EUR |
EUR |
EUR |
EUR |
|
|
|
profit and |
profit and |
profit and |
profit and |
|
|
|
loss account |
loss account |
loss account |
loss account |
|
|
|
|
|
|
|
|
Net sales |
|
761.338.071 |
745.334.197 |
660.434.873 |
623.084.466 |
|
|
|
|
|
|
|
|
Changes in the value of inventories of products and work-in-process |
|
9.178.746 |
1.710.510 |
18.137.595 |
|
|
Capitalised own products and own services |
|
0 |
0 |
0 |
|
|
Other operating revenues (with subventions, grants,...) |
|
1.401.138 |
18.298.578 |
2.497.877 |
|
|
GROSS OPERATING YIELD |
|
771.917.955 |
765.343.285 |
681.070.345 |
|
|
Cost of goods, material and services |
|
488.982.248 |
479.017.590 |
427.323.471 |
|
|
Purchase value of goods and materials sold and |
|
365.137.353 |
358.326.732 |
310.374.089 |
|
|
cost of material and cost of material used |
|
|
|
|
|
|
Cost of services |
|
123.844.895 |
120.690.858 |
116.949.382 |
|
|
Labour cost |
|
155.621.090 |
142.753.510 |
133.929.946 |
|
|
Cost of wages |
|
115.832.016 |
106.049.507 |
94.448.150 |
|
|
Cost of pension insurance |
|
15.431.445 |
14.177.033 |
13.361.029 |
|
|
Cost of other social insurance |
|
8.426.958 |
8.074.950 |
6.720.876 |
|
|
Other labour cost |
|
15.930.671 |
14.452.020 |
19.399.891 |
|
|
Write-offs |
|
56.502.333 |
50.966.095 |
46.504.345 |
|
|
Depreciation |
|
53.137.825 |
50.824.041 |
45.440.965 |
|
|
Revaluation operating expenses for non-tangible assets and tangible fixed assets |
|
3.169.069 |
141.949 |
272.285 |
|
|
Revaluation operating expenses for current assets |
|
195.439 |
105 |
791.095 |
|
|
Other operating expenses |
|
2.549.426 |
2.368.637 |
2.207.383 |
|
|
OPERATING REVENUES |
|
762.739.209 |
763.632.775 |
662.932.750 |
|
|
OPERATING EXPENSES |
|
703.655.097 |
675.105.832 |
609.965.145 |
|
|
OPERATING RESULT |
|
59.084.112 |
88.526.943 |
52.967.605 |
|
|
EBIT |
|
68.262.858 |
90.237.453 |
71.105.200 |
79.915.688 |
|
Financial income from investments in other enterprises |
|
10.018.735 |
9.028.655 |
11.610.802 |
6.550.476 |
|
Financial income from loans |
|
37.643 |
48.868 |
465.302 |
1.288.149 |
|
Financial income from operating receivables |
|
2.867.233 |
1.863.629 |
4.755.375 |
4.621.707 |
|
Financial expenses from depreciation and write- |
|
0 |
0 |
0 |
0 |
|
offs of financial investments |
|
|
|
|
|
|
Financial expenses from financial liabilities |
|
1.701.700 |
1.634.712 |
2.569.266 |
524.982 |
|
Financial expenses from operating liabilities |
|
2.791.630 |
3.275.467 |
5.507.228 |
3.637.753 |
|
Financial income |
|
12.923.611 |
10.941.152 |
16.831.479 |
12.460.332 |
|
Financial expenses |
|
4.493.330 |
4.910.179 |
8.076.494 |
4.162.735 |
|
Other revenues |
|
675 |
140.277 |
9.038 |
1.887 |
|
Other expenses |
|
85.532 |
59.439 |
127.710 |
139.941 |
|
Total revenues |
|
784.842.241 |
776.424.714 |
697.910.862 |
645.328.141 |
|
Total costs |
|
708.233.959 |
680.075.450 |
618.169.349 |
557.252.910 |
|
Total business result |
|
76.608.282 |
96.349.264 |
79.741.513 |
88.075.231 |
|
Tax on profit |
|
7.468.186 |
7.513.437 |
5.348.397 |
14.403.087 |
|
|
|
31/12/2014 |
31/12/2013 |
31/12/2012 |
31/12/2011 |
|
|
|
1 |
1 |
1 |
1 |
|
Name |
Ref. |
EUR |
EUR |
EUR |
EUR |
|
|
|
profit and |
profit and |
profit and |
profit and |
|
|
|
loss account |
loss account |
loss account |
loss account |
|
Deferred taxs |
|
-157.272 |
0 |
-1.537.054 |
-188.048 |
|
Net business result for the accounting period |
|
69.297.368 |
88.835.827 |
75.930.170 |
73.860.192 |
Financial
Ratios
|
Name |
Ref. |
31/12/2014 |
31/12/2013 |
31/12/2012 |
31/12/2011 |
|
Equity ratio |
1 |
0,05 |
0,06 |
0,06 |
0,06 |
|
Cleared equity ratio |
2 |
0,06 |
0,06 |
0,06 |
0,06 |
|
Current liquidity |
3 |
0,75 |
0,81 |
0,86 |
0,90 |
|
Quick liquidity |
4 |
0,29 |
0,32 |
0,38 |
0,56 |
|
Working capital |
5 |
-89934695,00 |
-54816686,00 |
-42685291,00 |
-31943321,00 |
|
Gearing |
6 |
18,67 |
17,61 |
17,96 |
18,04 |
|
Cleared gearing |
7 |
4,44 |
3,57 |
4,11 |
0,44 |
|
Profitability |
8 |
9,76 |
12,41 |
11,43 |
13,65 |
|
Operating profitability |
9 |
8,83 |
11,44 |
10,88 |
11,45 |
|
Stock days |
10 |
76,70 |
66,80 |
77,75 |
63,56 |
|
Debtor days |
11 |
47,36 |
43,07 |
60,23 |
66,59 |
|
Supplier days |
12 |
60,10 |
54,47 |
57,63 |
172,04 |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.63.60 |
|
|
1 |
Rs.100.09 |
|
Euro |
1 |
Rs.71.23 |
INFORMATION DETAILS
|
Analysis Done by
: |
RAS |
|
|
|
|
Report Prepared
by : |
ANK |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s
credit risk and to set the amount of credit to be extended. It is calculated
from a composite of weighted scores obtained from each of the major sections of
this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or
its officials.